Evidence map›Paper›PMID 37235349›Full record

ArticleToxins2023

Replacement of the Mouse LD

Elena Fonfria, Elizabeth Marks, Lisa-Marie Foulkes, Rebecca Schofield, Daniel Higazi, Sam Coward, Alistair Kippen

Abstract read
In one paragraph

Article in Toxins, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elena FonfriaIpsen Bioinnovation, Abingdon OX14 4RY, UK.ORCID 0000-0001-8816-519X
Elizabeth MarksIpsen Biopharm Ltd., Wrexham LL13 9UF, UK.
Lisa-Marie FoulkesIpsen Biopharm Ltd., Wrexham LL13 9UF, UK.
Rebecca SchofieldIpsen Biopharm Ltd., Wrexham LL13 9UF, UK.
Daniel HigaziIpsen Biopharm Ltd., Wrexham LL13 9UF, UK.
Sam CowardIpsen Biopharm Ltd., Wrexham LL13 9UF, UK.
Alistair KippenIpsen Biopharm Ltd., Wrexham LL13 9UF, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Botulinum neurotoxins (BoNTs) are important therapeutic agents. The in vivo median lethal dose (LD

Indexed as

Botulinum Toxins, Type ANeurotoxinsAnimalsLethal Dose 50MicePowdersabobotulinumtoxinABotulinum Toxins, Type ANeurotoxinsPowdersbotulinumCBALD50potencyreplacementtoxin

Identifiers

PMID37235349
PMCPMC10220824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.